Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease-Reference-Cited by-同舟云学术

Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease

Published:2004-09 Issue:5 Volume:2 Page:729-743
ISSN:1477-9072
Container-title:Expert Review of Cardiovascular Therapy
language:en
Short-container-title:Expert Review of Cardiovascular Therapy

Author:

Kronenberg Florian

Publisher

Informa UK Limited

Subject

Cardiology and Cardiovascular Medicine,General Medicine,Internal Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1586/14779072.2.5.729

Reference121 articles.

1. Stable Angina in Advanced CKD

2. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease.Am. J. Kidney Dis. 41\(Suppl. 3), S1—S92 (2003).

3. Lipoprotein(a) in renal disease

4. Lipoprotein(a), fibrin binding, and plasminogen activation.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elevated lipoprotein(a) levels predict cardiovascular disease in type 2 diabetes mellitus: a 10-year prospective cohort study;The Korean Journal of Internal Medicine;2016-11-01

2. Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention;International Journal of Cardiology;2016-02

3. Lipoprotein(a) predicts a new onset of chronic kidney disease in people with Type 2 diabetes mellitus;Diabetic Medicine;2015-09-07

4. Relation of Serum Lipids and Lipoproteins with Progression of CKD: The CRIC Study;Clinical Journal of the American Society of Nephrology;2014-05-15

5. Metabolic Traits as Intermediate Phenotypes;Genetics Meets Metabolomics;2012